3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Precancerous Conditions
51
Leukemia
13
Lymphoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Multiple Myeloma
10
Neoplasms, Plasma Cell
9
Myelodysplastic Syndromes
9
Lymphoma, Non-Hodgkin
9
Lymphoma, Mantle-Cell
9
Lymphoma, Large-Cell, Immunoblastic
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia, Myeloid, Acute
9
Burkitt Lymphoma
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Myeloproliferative Disorders
8
Monoclonal Gammopathy of Undetermined Significance
8
Lymphoma, Large-Cell, Anaplastic
8
Immunoblastic Lymphadenopathy
8
Hodgkin Disease
8
Waldenstrom Macroglobulinemia
7
Lymphoma, T-Cell, Cutaneous
7
Leukemia, Biphenotypic, Acute
7
Uterine Cervical Dysplasia
6
Primary Myelofibrosis
6
Leukemia, Prolymphocytic
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Interventions
trametinib
1
dabrafenib
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Rare Malignant Neoplasm
×
Other neoplasm
×
Clear all
NCT06119789
2025-03-26
MATRIX-Rare
Oslo University Hospital
Phase 2
Recruiting
96 enrolled